Penumbra introduces new advancements in stroke thrombectomy aspiration technology

Penumbra, Inc., a global healthcare company focused on innovative therapies, today announced U.S. commercial availability of the Penumbra System's most advanced technology: Penumbra JET 7 and Penumbra JET D Reperfusion Catheters powered by the Penumbra ENGINE aspiration source. All are part of the fully integrated Penumbra System® that utilizes aspiration-based mechanical thrombectomy for stroke revascularization. The Penumbra JET 7 and JET D Reperfusion Catheters deliver deep vacuum aspiration power of the Penumbra ENGINE to enable physicians to extract thrombus effectively and safely in acute ischemic stroke patients.

The Penumbra JET 7 is the Penumbra System's seventh generation reperfusion catheter for proximal large vessel occlusions, and JET D Reperfusion Catheter is designed specifically for distal occlusions. JET 7 Reperfusion Catheter has a large 0.072" lumen for deep vacuum aspiration and is designed for trackability and navigation, featuring 20 transitions from the proximal shaft to distal tip, a progressive distal coil wind for superior flexibility and Quad-Wire technology in the proximal shaft for enhanced pushability. JET D brings deep vacuum aspiration power to distal occlusions with a smaller profile.

"The JET 7 Reperfusion Catheter with its advanced tracking technology and large 0.072" aspiration lumen is the most advanced device for stroke. In my clinical experience, I was able to easily and quickly navigate the JET 7 through tortuous anatomy to the face of the clot and achieve full revascularization after a single pass," said Alejandro M. Spiotta, MD, Medical University of South Carolina, Charleston, S.C. "We know from our own published experience that increases in aspiration lumen size have led to faster recanalization times and higher likelihood of success at first pass without compromising safety. I eagerly await collecting and publishing our clinical experience with JET 7."

Both JET 7 and JET D are supported by Penumbra's third generation aspiration source, Penumbra ENGINE, which offers the deepest vacuum available with the Penumbra System. Penumbra ENGINE offers near perfect vacuum (-29.2 in Hg) and features a new sleek simple design with one-touch aspiration control, a new canister with integrated clot catcher and LED canister lighting. Together, the Penumbra System with the new Penumbra JET 7 Reperfusion Catheter powered by the Penumbra ENGINE offers the highest thrombus removal force for revascularization of acute ischemic stroke patients with large vessel occlusions.

"The JET 7 and JET D along with the new ENGINE provide a suite of tools to effectively address both proximal and distal occlusions," said Ian Kaminsky, MD, MS, Radiology Imaging Associates/Swedish Medical Center, Englewood, Colorado. "In our initial case experience, we saw the easy tracking of the JET 7 and JET D in a range of tortuous conditions and vessel locations that, combined with the deep vacuum of the ENGINE, offer the potential to increase our rate of complete first pass revascularization while decreasing procedure times."

"Penumbra is delighted to usher in our next phase of innovation with the introduction of the Penumbra JET 7, JET D and ENGINE," said Adam Elsesser, chairman and chief executive officer of Penumbra. "Each phase of innovation - original Penumbra System, MAX™ and ACE™ systems, and now JET and ENGINE - represents a significant improvement in performance and the opportunity to further help patients experiencing acute ischemic stroke."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Edoxaban proves effective in preventing blood clots, stroke after heart valve surgery